Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Official Title

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Summary:

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

Trial Description

Primary Outcome:

  • Number of treatment-emergent adverse events
Secondary Outcome:
  • Overall Response Rate
  • Symptom Response Rate
  • Anemia response
  • Duration of Anemia Response
  • Rate of red blood cell (RBC) transfusion dependency
  • Percentage change in Spleen Volume
  • Spleen length response

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society